Adverse Reactions in Treatment-Naive Adults & Adolescents

Discontinuation rates due to adverse reactions (ARs) and adverse reaction profile


Studies 104/111 pooled: Treatment-naive adults

Discontinuation rates due to ARs through Week 481
of adults who received the FTC/TAF backbone + EVG/COBI* discontinued treatment due to ARs
of adults who received the FTC/TDF backbone + EVG/COBI* discontinued treatment due to ARs
  • In Studies 104/111 pooled, there were no discontinuations due to renal ARs in the FTC/TAF backbone + EVG/COBI* arm vs 4 discontinuations in the FTC/TDF backbone + EVG/COBI* arm1

ARs through Week 482
ARs (all grades) reported in ≥5% of treatment-naive adults receiving the FTC/TAF backbone + EVG/COBI* FTC/TAF +
EVG/COBI*

(%) (n=866)
FTC/TDF +
EVG/COBI*
(%) (n=867)
Gastrointestinal disorders
Diarrhea 7 9
Nausea 10 13
General disorders and administration site conditions
Fatigue 5 4
Nervous system disorders
Headache 6 5
  • Treatment-naive adults taking the FTC/TAF backbone + EVG/COBI* (n=866) experienced a greater increase in serum lipids compared with adults taking the FTC/TDF backbone + EVG/COBI* (n=867)3
    • Mean total-cholesterol-to-HDL ratio increased by 0.2 in those adults taking the FTC/TAF backbone + EVG/COBI* vs no change in those taking the FTC/TDF backbone + EVG/COBI2*
    • 5% of adults taking the FTC/TAF backbone + EVG/COBI* experienced fasted LDL-cholesterol levels >190 mg/dL vs 2% of those taking the FTC/TDF backbone + EVG/COBI2*
Studies 104/111 pooled: Laboratory abnormalities (Grades 3-4) reported in ≥2% of treatment-naive adults through Week 482

Treatment-emergent laboratory abnormalities
FTC/TAF +
EVG/COBI*
(%) (n=866)
FTC/TDF +
EVG/COBI*
(%) (n=867)
Creatine kinase (≥10.0 x ULN) 7 6
LDL-cholesterol (fasted) (>190 mg/dL) 5 2
Total cholesterol (fasted) (>300 mg/dL) 2 1
See the Studies 104/111
Pooled Study Design

Adverse reactions

  • Most common adverse reaction (incidence ≥10%; all grades) in clinical studies was nausea (10%).

Study 106: Treatment-naive adolescents

Discontinuation rates due to ARs through Week 242
adolescents who received the FTC/TAF backbone + EVG/COBI* discontinued treatment due to ARs

  • In 23 adolescents who received treatment with the FTC/TAF backbone + EVG/COBI,* the safety profile was similar to that observed in treatment-naive adults4
  • One adolescent developed unexplained uveitis while receiving the FTC/TAF backbone + EVG/COBI* that resolved and did not require discontinuation2
See the Study 106 Study Design

Important Safety Information

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

  • DESCOVY® is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of DESCOVY have not been established in patients coinfected with HIV-1 and HBV. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of DESCOVY. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue DESCOVY. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

Warnings and precautions

  • Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported.
  • New onset or worsening renal impairment: Cases of acute renal failure and Fanconi syndrome have been reported with the use of tenofovir prodrugs. In clinical trials of FTC and tenofovir alafenamide with elvitegravir and cobicistat, there have been no cases of Fanconi syndrome or proximal renal tubulopathy (PRT). Do not initiate DESCOVY in patients with estimated creatinine clearance (CrCl) <30 mL/min. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue DESCOVY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.
    Renal monitoring: In all patients, monitor CrCl, urine glucose, and urine protein prior to initiating and during therapy. In patients with chronic kidney disease, additionally monitor serum phosphorus.
  • Lactic acidosis and severe hepatomegaly with steatosis: Fatal cases have been reported with the use of nucleoside analogs, including FTC and TDF. Discontinue DESCOVY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.
  • Bone loss and mineralization defects: Decreases in bone mineral density (BMD) have been reported with the use of tenofovir prodrugs. Consider monitoring BMD in patients with a history of pathologic fracture or risk factors for bone loss. Mineralization defects, including osteomalacia associated with PRT, have been reported with the use of TDF-containing products.

Adverse reactions

  • Most common adverse reaction (incidence ≥10%; all grades) in clinical studies was nausea (10%).

Drug interactions

  • Prescribing information: Consult the full prescribing information for DESCOVY for more information on potentially significant drug interactions, including clinical comments.
  • Metabolism: Drugs that inhibit P-gp can increase the concentrations of components of DESCOVY. Drugs that induce P-gp can decrease the concentrations of components of DESCOVY, which may lead to loss of efficacy and development of resistance.
  • Drugs affecting renal function: Coadministration of DESCOVY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of emtricitabine and tenofovir and the risk of adverse reactions.

Dosage and administration

  • Dosage: Patients 12 years and older who weigh ≥35 kg: 1 tablet taken orally once daily with or without food.
  • Renal impairment: Not recommended in patients with CrCl <30 mL/min.
  • Testing prior to initiation: Test patients for HBV infection and assess CrCl, urine glucose and urine protein.

Pregnancy and lactation

  • Pregnancy: There is insufficient human data on the use of DESCOVY during pregnancy. An Antiretroviral Pregnancy Registry (APR) has been established; available data from the APR for FTC shows no difference in the rates of birth defects compared with a US reference population.
  • Lactation: Women infected with HIV-1 should be instructed not to breastfeed, due to the potential for HIV-1 transmission.

Indication

DESCOVY® is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients 12 years and older.

Limitations of Use:
DESCOVY is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.

*Administered as an STR.


References:

  1. Sax PE, Wohl D, Yin MT, et al; for GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606-2615.
  2. Data on file. Gilead Sciences, Inc.
  3. Sax P, Saag M, Yin MT, et al. Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate. Presented at 2015 Conference on Retroviruses and Opportunistic Infections (CROI 2015); February 23-24, 2015; Seattle, WA. Abstract 143LB.
  4. DESCOVY [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2017.